The company released new data from the MAXA clinical trial which compared standalone MagnetOS to the gold standard autograft in the posterior spinal fusion approach. The study found MagnetOS had a fusion rate of 78% after one year compared to 45% with the autograft.
MagnetOS Easypack puttyputty earned FDA 510(k) clearances. MagnetOs Easypack putty can be used in any interbody spaces and cages approved for use with bone void fillers.
Magnet OS putty was also cleared by the FDA for standalone use or mixed with an autograft.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
